However, relying solely on in vitro selection can yield a limited set of candidates, since the screening is affected by multiple factors including the initial clonal frequency, the screening conditions, and other experimental parameters. This means that, if the screening process is performed accurately, there is the potential of discovering a large number of binders against most targets. These antibody libraries can reach repertoire sizes of 1010-11 unique clones, which goes at least an order of magnitude above the estimated in vivo circulating B cell diversity of 107-9. Typically, three to four rounds of panning are performed before acquiring promising leads.ĭiverse types of libraries can be used in display technologies, such as naïve, immunized, and even synthetic and semi-synthetic antibody repertoire libraries. The iteration of these screening rounds, also known as ‘panning rounds’, aim to enrich the library for antibodies specific for the target. The weak or non-binders are washed away during the screening process while the strong binders remain bound to the antigen and are amplified before the next selection round. In display technologies, Fab, scFv, VHH, or other antibody constructs are recombinantly expressed in display organisms (phage, yeast, mammalian cell, or cell-free), which are then repeatedly screened for binding against the antigen. In this blog, we will discuss display technologies, enrichment analysis, and how the IGX Platform can help you make the best out of your display-based antibody discovery campaigns.ĭisplay technologies offer high-throughput discovery workflows with control over the initial antibody repertoire and the candidate selection process. Display technologies offer alternative platforms that can improve scalability and research scope at a lower cost compared to single B-cell technologies. The innovative single B-cell discovery platforms address these concerns, but the equipment and setup costs may be too high for many research groups to integrate it into their workflow. Traditional hybridoma-based discovery approaches are suffering from low scalability and a saturated ecosystem, in which most ‘low-hanging fruit’ antibodies have already been discovered. The pharmaceutical industry has been trying to further increase the value out of their drug discovery campaigns to accelerate delivery to market and reduce research costs.
0 kommentar(er)
